Search results
Oramed Pharma Shares Sink After Diabetes Candidate Fails In Phase 3 Study
Benzinga via Yahoo Finance· 1 year agoOramed Pharmaceuticals Inc (NASDAQ: ORMP) announced top-line results from its Phase 3 trial...
Living Well with Type 2 Diabetes
Prevention via Yahoo News· 9 months agoWith strategic lifestyle habits, you can not only manage your diabetes, but also lower your risk of common health issues that go along with the...
Why Better Therapeutics Shares Are Surging During Premarket Session
Benzinga via Yahoo Finance· 2 years agoBetter Therapeutics Inc (NASDAQ: BTTX) completed the pivotal clinical trial for BT-001, an...
What Is Diabetes Mellitus?
Health via Yahoo News· 9 months agoDiabetes mellitus—more commonly known as diabetes—is a chronic disease that occurs when you have higher than normal levels of blood glucose (or, blood...
Oramed Pharma Shares Fall After Additional Data From Oral Insulin Study
Benzinga via Yahoo Finance· 2 years agoOramed Pharmaceuticals Inc (NASDAQ: ORMP) has announced additional data from its Phase 2 trial...
Novo Nordisk's (NVO) Shares Jump 17% in a Month: Here's Why
Zacks via Yahoo Finance· 9 months agoShares of Novo Nordisk NVO have risen 17.1% in the past month compared with the industry’s 5.0%...
Here Are 25 Billion Reasons to Invest in Eli Lilly
Motley Fool· 2 years agoEli Lilly (NYSE: LLY) and its shareholders are sitting pretty right now. Eli Lilly owes this performance to a combination of factors. The drugmaker...
Biomea Fusion (BMEA) Stock Surges 41% in a Month: Here's Why
Zacks via Yahoo Finance· 6 months agoBiomea Fusion (BMEA) rises 41% in a month on the back of positive investor expectations regarding...
The Zacks Analyst Blog Highlights Stocks recently featured in the blog include: Novo Nordisk, Eli...
Zacks via Yahoo Finance· 2 weeks agoFor Immediate Releases Chicago, IL – May 20, 2024 – Zacks.com announces the list of stocks featured...
Roche (RHHBY) Posts Encouraging Phase I Obesity Drug Data
Zacks via Yahoo Finance· 3 weeks agoData from the study shows that nearly half of the patients who received Roche's (RHHBY)...